IL17A and Psoriasiform dermatitis: The therapeutic landscape for psoriasiform dermatitis is evolving, with emerging data on the efficacy of targeted agents such as JAK inhibitors, PDE4 inhibitors, and biologics directed against IL-17 and IL-23.